Palisade Bio Inc. has announced that two abstracts featuring its lead program, PALI-2108, have been selected for poster presentations at two major international inflammatory bowel disease $(IBD)$ conferences in early 2026. The presentations will highlight translational findings from a Phase 1a study of PALI-2108, a gut-targeted PDE4 inhibitor, focusing on its clinical, histologic, and biomarker effects in ulcerative colitis. The results will be presented at the Crohn's & Colitis Congress 2026 in Las Vegas on January 23, 2026, and at the 21st Congress of ECCO in Stockholm on February 20, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9626761-en) on January 16, 2026, and is solely responsible for the information contained therein.